Inhaled treprostinil shows promise for exercise in PAH-ILD patients
NCT ID NCT05564637
First seen Dec 29, 2025 · Last updated May 14, 2026 · Updated 24 times
Summary
This study looked at how an inhaled drug called treprostinil affects exercise ability in people with pulmonary hypertension caused by interstitial lung disease. 29 participants took the drug for 3 months. Researchers measured heart function and breathing efficiency during exercise to see if the drug helps improve oxygen flow and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.